410 results about "Granulocyte" patented technology

The invention relates to the technical field of detection kits, in particular to a detection kit for neutrophil gelatinase-associated lipocalin and a preparation method of the detection kit. The invention provides a detection kit for neutrophil gelatinase-associated lipocalin. The detection kit comprises an independently packaged reagent R1 and an independently packaged reagent R2, the reagent R1 comprises an HBR series specific blocking agent; the reagent R2 comprises carboxyl latex microspheres coupled with an NGAL antibody; the carboxyl content of the carboxyl latex microspheres is greater than 100 [mu] eq / g, and the particle size is 100-400 nm. According to the kit, an HBR series specific blocking agent is used as a component of the reagent R1, so that endogenous interference is reduced, and false positive and negative detection results of a sample are avoided. Furthermore, the latex with proper particle size is selected to be coupled with the polyclonal antibody, and the sealing condition is optimized, so that the method has the advantages of wide linearity, good analysis sensitivity, simplicity in operation, controllable batch difference and controllable cost.

The invention relates to a culture medium and a culture method of persistent DC-CIK cells and application of the culture medium and the culture method, and belongs to the technical field of cell culture. The invention provides a culture medium for persistent DC-CIK cells, which takes a serum-free culture medium as a solvent and comprises a recombinant human granulocyte macrophage colony stimulating factor, a recombinant human interleukin-12, a recombinant human tumor necrosis factor-alpha, a recombinant human interferon-gamma, L-cysteine, glutathione, ginseng polysaccharide and streptomycin sulfate. According to the culture medium and the culture method of the persistent DC-CIK cells, proliferation and growth of the DC-CIK cells can be promoted, and very high tumor killing activity of the DC-CIK cells can be maintained for a long time.

Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.

The invention discloses a strain of Lactobacillus paracasei SX-G1520 and an application of the Lactobacillus paracasei SX-G1520 in preparation of a lipid-lowering, anti-inflammatory and / or antioxidant product, the preservation number of the Lactobacillus paracasei SX-G1520 is CCTCC (China Center for Type Culture Collection) No: M 2025032, and the Lactobacillus paracasei SX-G1520 is preserved in the China Center for Type Culture Collection on January 6, 2025. The Lactobacillus paracasei SX-G1520 strain provided by the invention has lipid-lowering and antioxidant functions, significantly reduces the content of intestinal neutrophils of a zebra fish inflammatory bowel disease model, shows a significant effect on relieving intestinal inflammation, is good in safety, and has good application prospects. And a new technical choice is provided for developing probiotic preparations for regulating fat metabolism, resisting oxidative stress and preventing and treating inflammatory bowel diseases.

The invention discloses a reagent for rapidly distinguishing bacterial and virus infection and application, belongs to the field of molecular biology, relates to medical and biotechnology, and aims to solve the problem that a traditional method cannot clearly distinguish bacterial infection from virus infection. The reagent comprises five antibodies marked with different fluorescence. The five antibodies are all mouse anti-human or rabbit anti-human antibodies, and targets corresponding to the five antibodies are respectively CD45, CD14, CD64, CD169 and HLA-DR (human leukocyte antigen-DR). The tail end of the antibody is connected with different fluorescein through chemical reaction; fluorescence labeling is performed on neutrophils, mononuclear cells and lymphocytes in peripheral blood through an antibody combination of CD molecules, and corresponding infection indexes are calculated through a flow cytometry method, so that the infection type (bacterial / virus infection) of a patient is quickly distinguished and judged.

The invention relates to the technical field of disease curative effect evaluation, and discloses a method for evaluating the curative effect of granulocyte deficiency accompanying fever after hematologic tumor chemotherapy based on machine learning, and the method comprises the steps: S1, collecting and preprocessing multi-center medical data, the data comprising structured clinical data and multi-modal unstructured data; s2, a curative effect prediction model is constructed based on a graph neural network, and a central moment constraint-based graph federal learning training model is adopted, wherein a patient graph is constructed as an original graph and an enhanced graph is generated; respectively processing the original image and the enhanced image through a two-channel image convolutional neural network, and extracting a high-order representation vector; constructing an enhanced perception loss function based on the high-order representation vectors of the original image and the enhanced image; combining a federated learning framework with multi-center data to train a model; and S3, predicting a curative effect evaluation result through the trained curative effect prediction model. The accuracy, the stability and the clinical interpretability of curative effect evaluation are improved.

The invention discloses a salt of ponabulin and application thereof, relates to the field of medicinal chemistry, and solves the problem that the curative effect is influenced by poor water solubility of ponabulin in the prior art. The invention provides a plurality of ponabulin salts, the salts are formed by ponabulin and inorganic acid or organic acid, and the structure of the ponabulin is shown as a formula I. The invention further provides a preparation method of the ponabulin salt. In addition, the invention finds that the solubility of p-toluenesulfonate and 1, 5-naphthalene disulfonate of ponabulin in water is remarkably improved by more than 2000 times compared with free alkali, so that the requirement that a solubilizer is not added or a few solubilizers are added in the injection preparation process can be met, and potential harm to human health in the long-term use process of the solubilizers can be prevented. Pharmacodynamic tests show that the salt of the ponabulin has good anti-tumor activity and an effect of relieving neutropenia, and is suitable for preparing anti-tumor drugs. # imgabs0 #

The invention provides a neutrophil differentiation trajectory inference method and system, and relates to the technical field of cell differentiation trajectory analys.The neutrophil differentiation trajectory inference method comprises the following steps that gene expression data of neutrophil are obtained, and feature selection processing is conducted on the gene expression data of the neutrophil; performing feature mapping processing on the gene expression data set based on a deep learning method; evaluating scores of the alternative models by using a Bayesian information criterion, and screening the alternative model with the highest score as an optimal causal model according to a scoring result; and constructing a differentiation trajectory network according to the causal relationship network in the optimal model, and performing differentiation trajectory inference on the neutrophile granulocytes according to the differentiation trajectory network to obtain a prediction result of the neutrophile granulocyte differentiation trajectory. According to the method, the prediction result of the neutrophil differentiation trajectory can be obtained, and the dynamic process and regulation mechanism of neutrophil differentiation can be disclosed.

The present invention discloses an enhanced tumor vaccine adjuvant, and specifically relates to the field of vaccine adjuvants, the adjuvant comprising granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-9 (IL-9), gamma interferon (IFN-γ) and at least one additional immunomodulatory factor, wherein the immunomodulatory factor is selected from tumor-specific antigen WT1, CD40 ligand (CD40L), Toll-like receptor agonist or a combination thereof. The tumor vaccine adjuvant of the present invention can enhance the body's immune response to the tumor vaccine and improve the prevention and treatment effect of the tumor vaccine on tumors.

The antibody disclosed by the invention can specifically target high-virulence klebsiella pneumoniae of different serotypes, and specifically targets klebsiella pneumoniae of K1 and K2 serotypes. The antibody disclosed by the invention can be combined with high-toxicity klebsiella pneumoniae extracellular capsular polysaccharide with high affinity, has very strong neutralizing activity on klebsiella pneumoniae, and can mediate complement and mature neutrophil to neutralize and kill bacteria in an in-vitro killing experiment, so that the bacterial density is reduced, and the killing effect is improved. The traditional Chinese medicine composition can effectively prevent and treat high-toxicity klebsiella pneumoniae clinical infection and effectively improve pulmonary infection, provides a way for solving the problems of klebsiella pneumoniae infection and multiple drug resistance, has remarkable significance in preventing, diagnosing and treating klebsiella pneumoniae infection, and has important value in development of a new generation of klebsiella pneumoniae medicine.

The invention belongs to the field of small molecule compound medicines, and relates to application of an APE1 inhibitor in preparation of a medicine for treating nasosinusitis. The present application finds a new target APE1 for treating nasosinusitis, and achieves effective treatment of nasosinusitis by an APE1 inhibitor (including a C10 compound), in which the C10 compound shows a very excellent therapeutic effect, significantly inhibits pathological symptoms of nasosinusitis, including relieving Th2 inflammation, reducing eosinophilic granulocyte infiltration, improving nasal barrier integrity damage, and preventing or treating nasosinusitis. And the nasal mucosa neovascularization is prevented by inhibiting the generation of VEGF and other cell factors, and the inflammatory response of chronic nasosinusitis is effectively relieved. In addition, the C10 compound is simple in structure and easy to synthesize, has good patent medicine characteristics, and has good industrialization prospects.

The invention provides an application of a compound as shown in a formula I, cis-trans isomers, enantiomers, diastereoisomers, racemes, solvates, hydrates or pharmaceutically acceptable salts or prodrugs of the compound in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury, and application of the compound in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury. The compound shown in the formula I can obviously reduce proinflammatory cytokine tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) of an acute lung injury rat model, improve infiltration of inflammatory cells (including mononuclear / macrophage, lymphocyte and neutrophil) in lung tissues, improve pathological injury of the lung tissues, improve lung functions, and improve the curative effect of the lung. The above results show that the compound represented by the formula I can be used for prevention, alleviation, adjuvant therapy or treatment of lung injury, especially acute lung injury or a combined disease thereof or acute respiratory distress syndrome or a combined disease thereof.

The invention relates to an antibody composition, a kit and a system for rapidly screening acute promyelocytic leukemia. The antibody composition comprises a first group of antibodies, a second group of antibodies and a third group of antibodies, the first group of antibodies comprises a CD71 antibody, a CD33 antibody, a CD117 antibody, a CD34 antibody, an HLA-DR antibody, a CD19 antibody, a CD10 antibody, a CD7 antibody and a CD45 antibody; the second group of antibodies comprises a CD38 antibody, a CD56 antibody, a CD16 antibody, a CD34 antibody, a CD13 antibody, a CD11b antibody, a CD64 antibody, a CD15 antibody and a CD45 antibody; the third group of antibodies comprises a CD9 antibody, an MPO antibody, a CD117 antibody and a CD45 antibody; and each antibody is a monoclonal antibody marked with a detection marker. The antibody composition comprises a CD117 + CD33 + region as a main target cell population, and covers three groups of antibodies for identifying acute promyelocytic leukemia, such as CD33, CD34, CD64, CD13, CD9 and MPO, the acute promyelocytic leukemia can be rapidly, simply and conveniently detected by adopting the antibody composition, the detection sensitivity is high, the specificity is high, the accuracy rate is high, and the antibody composition can be widely applied to detection of acute promyelocytic leukemia. The acute promyelocytic leukemia patient can be accurately and quickly identified, and early diagnosis and early treatment are realized.

The invention provides an anti-inflammatory and anti-vascular bidirectional trapping combined self-luminous power compound based on neutrophil nano-vesicles as well as a preparation method and application thereof, and belongs to the technical field of biological medicine manufacturing. The compound takes a neutrophil nano-vesicle as a carrier, and is also loaded with bis (2, 4, 5-trichlorosalicylic acid n-amyl ester) oxalate (CPPO) and a photosensitizer Ce6, and meanwhile, the surface of the compound is modified with ranibizumab through ketal mercaptan responded by ROS (reactive oxygen species). The compound has the characteristics of trapping anti-inflammatory factors and spontaneously targeting corneal neovascularization diseased regions, Ranibizumab is responsively released on the basis of ROS to be combined with vascular endothelial growth factors, the anti-angiogenesis function is achieved, meanwhile, chemical energy generated by CPPO under the high-oxygen condition stimulates Ce6 to generate singlet oxygen, and therefore the vascular endothelial cell tubulogenesis capacity is inhibited. The invention provides a new means for treatment of eye disease related diseases.

The invention belongs to the technical field of biology, and particularly relates to a reagent and a kit for detecting eosinophilic granulocyte chronic sinusitis with nasal polyp. The detection reagent comprises the following components: a substance which is used for detecting the Galectin-10 protein (Charcot-Leyden Crystal, CLCs) in a crystalline state, and a detection reagent which is used for detecting the Galectin-10 protein (Charcot-Leyden Crystal, CLCs) in the crystalline state. The reagent for detecting CLCs comprises a mixture of eosin, glacial acetic acid and water. The mass volume ratio of eosin to glacial acetic acid is 1: (1-50) g / mL, and the volume ratio of glacial acetic acid to water is 1: (2-100). According to the invention, the reagent capable of efficiently detecting the CLCs is found for the first time, and the CLCs is a biomarker of the eosinophilic chronic sinusitis with nasal polyp, so that the detection reagent for the eosinophilic chronic sinusitis with nasal polyp is provided. By detecting CLCs, eosinophilic granulocyte chronic sinusitis with nasal polyp can be predicted, and the method is simple, convenient and fast and has good prediction performance.

The invention relates to the technical field of plant extracts, and provides a plant extract composition with synergistic hypoglycemic activity and application thereof, and the plant extract composition comprises a mulberry leaf extract, a white kidney bean extract and bitter gourd powder in a mass ratio of 8: (1-24): (1-64). By optimizing the mass ratio of the mulberry leaf extract, the white kidney bean extract and the bitter gourd powder, the blood sugar reducing effect of the plant extract taking the mulberry leaf extract, the white kidney bean extract and the bitter gourd powder as main raw materials is remarkably superior to that of a plant extract in the prior art. Meanwhile, the plant extract composition also has the effects of synergistically reducing the number of neutrophils around nerves, improving peripheral neuroinflammation, synergistically enhancing the fluorescence intensity of the peripheral nerves, improving peripheral nerve injury and inhibiting the enzymatic activity of a bacterium source dipeptidyl peptidase-4.

The present disclosure relates to methods of treating a subject suffering from an eosinophil-associated chronic obstructive pulmonary disease (COPD) or asthma-COPD overlap (ACO) using compounds that bind to CD131 and inhibit signalling of interleukin (IL) 3, IL-5 and granulocyte-macrophage colony stimulating factor (GM-CSF).

The invention relates to the technical field of artificial intelligence, in particular to a special child disease classification method based on particle-ball cross-granularity knowledge collaborative feature selection. The method comprises the following steps: firstly, providing a cross-granularity knowledge collaboration method based on granules and balls; further designing a fuzzy rough set model based on particle-ball cross-granularity knowledge collaboration to perform feature selection; according to the method, feature knowledge under different granularity levels is mined and coordinated to realize more robust and more efficient feature selection, so that the accuracy, generalization ability and interpretability of a classification model are improved, and a more reliable technical tool is provided for early screening and auxiliary diagnosis of diseases of special children.

The invention relates to the technical field of general image data processing or generation, in particular to a multi-view indirect immunofluorescence medical image classification interpretation method and system, and the method comprises the steps: mapping an ethanol view, a formaldehyde view and an HEp-2 view to a feature space, and converting into a feature sequence; performing position coding on the feature sequence to obtain position information; based on the feature sequence with the position information, modal identification information is added, and an identification feature sequence is determined; based on the identification feature sequence, executing multi-modal information fusion, and determining a multi-modal feature sequence; based on the multi-modal feature sequence, combining an attention mechanism to determine a long-distance dependency relationship and correlation between the data; and based on the attention mechanism model, outputting the probability of each category to execute classification interpretation. According to the method, the type of the anti-neutrophil cytoplasm antibody fluorescence model can be adaptively and comprehensively judged in combination with the characteristics of fluorescence brightness, forms and the like of different views, and interference existing in a single view is avoided.

The invention discloses lactobacillus paracasei CFCFC018, a microbial agent and application of the lactobacillus paracasei CFCFC018, and belongs to the technical field of microorganisms. The lactobacillus paracasei CFCFC018 is separated from intestinal contents of rural cats in half-farming and half-pastoral areas in Inner Mongolia, does not need genetic engineering modification, can highly express amino acids and neurotransmitters, can remarkably relieve mammary gland alveolar structure damage in mammary gland tissues of rats suffering from mastitis induced by staphylococcus aureus, and has the advantages of being high in safety and good in stability. The thickening of a mammary gland interacellular matrix layer is avoided, the infiltration number of neutrophils is reduced, the damage degree of mammary gland tissues is reduced, and a certain protection effect on the mammary gland tissues is achieved. The research also shows that the strain can reduce the abundance of harmful bacteria in excrement, improve intestinal inflammation and relieve edema of intestinal submucosa, which provides a new thought for preventing and treating mastitis by regulating intestinal microbiota.

The invention discloses a core-shell microneedle for removing bacterial biofilms and a preparation method of the core-shell microneedle, and belongs to the technical field of biological medicines. The core-shell microneedle comprises a shell layer and a core layer, the shell layer comprises a shell layer material and copper peroxide nanoparticles loaded on the shell layer material, and the core layer comprises a core layer material and mesoporous polydopamine nanoparticles loaded on the core layer material, coated with citraconate and capable of targeting neutrophils. The biofilm can penetrate through a biofilm and preferentially release copper peroxide nanoparticles, the oxidation-reduction steady state in the biofilm is destroyed, bacteria are killed, and the biofilm is dispersed; the polypeptide can target neutrophil, relieve the immunosuppression state of congenital immune cells and recover the bacterial killing ability of the congenital immune cells, so that escaped bacteria are effectively phagocytized; through the synergistic effect of the two, the biological membrane can be completely removed, the biological membrane removing agent has a clinical application prospect, and bacterial drug resistance caused by long-term use of antibiotics is reduced.

A method for treatment of a patient suffering from a cancer, an autoimmune disease, an infection, a neurodegenerative disease or any combination thereof is disclosed. Compositions and uses are also disclosed. The method includes providing fresh immune effector cells (IECs) armed with one or more multispecific antibodies, wherein the multispecific antibodies are bound to the fresh IECs; and administering an effective amount of a composition of cells to the patient, wherein the composition of cells comprises the multispecific antibody bound fresh IECs. The fresh IECs cab comprise a cell selected from the group consisting of peripheral blood mononuclear cells (PBMC), antigen-presenting cells. T cells (optionally fresh Bi Ab armed T cells (FBATs)). NK cells, monocytes, polymorphonuclear neutrophils (PMNs), and any combination thereof. Providing the fresh IECs can comprise isolating fresh IECs from the patient. Arming fresh IECs can be accomplished with one or more multispecific antibodies, wherein the multispecific antibodies are bound to the fresh IECs.

Disclosed herein are methods of reducing neutropenia that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.

NEO-201, an antibody that specifically binds to glycosylated peptides carrying core-1 and / or extended core-1 O-glycans comprised in CEACAM5 and CEAMCAM6, but does not bind to non-glycosylated CEACAM5 or non-glycosylated CEAMCAM6, has surprisingly shown to bind to and kill granulocyte myeloid-derived suppressor cells (gMDSC). The gMDSC is known to inhibit innate immunity in different cancers and infectious diseases, as well as other conditions. Based thereon, there is provided the use of NEO-201, alone or in combination, for the treatment of cancer and infectious diseases, as well as other conditions in which gMDSC inhibits innate immunity against the disease. The methods optionally include detecting the gMDSC before, during, or after the NEO-201 treatment. Diagnostic methods, therapeutic methods, and combination therapies using NEO-201, optionally in combination with another agent, to eliminate gMDSC and disease cells are also described.

The invention relates to the technical field of hepatic failure treatment, and particularly discloses application of tsRNA-20 or a simulant thereof in preparation of drugs for treating chronic plus acute hepatic failure and / or promoting liver cell proliferation. Through tsRNA sequencing and qRT-PCR verification, down-regulated expression of the tsRNA-20 in a plasma sample and liver tissue in chronic and acute hepatic failure is determined, and cell experiments find that the tsRNA-20 regulates an ACPH / GRHL1 axis to promote liver cell proliferation. Specifically, it is found that tsRNA-20 is combined with an amidyl peptide hydrolase (ACPH), so that a Ras-ERK pathway is activated, nuclear translocation of a granulocyte-like transcription factor 1 (GRHL1) is promoted, and finally liver cell proliferation is enhanced. Therefore, when the tsRNA-20, the precursor tRNA-GIy-CCC thereof and the regulated objects ACPH and GRHL1 thereof are applied to treatment of the chronic and acute liver failure, the tsRNA-20, the precursor tRNA-GIy-CCC thereof and the regulated objects ACPH and GRHL1 thereof can be used as targets to be regulated to promote liver cell proliferation, so that liver regeneration is promoted, the treatment effect of the chronic and acute liver failure is improved, the lifetime of patients with liver diseases is prolonged, and the tsRNA-20, the precursor tRNA-GIy-CCC and the regulated objects ACPH and GRHL1 possibly become new targets for precise treatment. The clinical application value is relatively high.

The invention discloses siRNA (small interfering Ribonucleic Acid) nanoparticles capable of efficiently targeting mononuclear phagocytes and mediated by intercellular effect of neutrophils as well as a preparation method and application of the siRNA nanoparticles. The siRNA nanoparticles comprise mesoporous silica nanoparticles carrying siRNA, and functional cell membranes over-expressing ICAM-1 ligands are wrapped outside the mesoporous silica nanoparticles carrying siRNA. Key sentinel cells (mononuclear phagocytes, MPs) for targeted mitochondrial DNA release to treat inflammatory responses caused by mtDNA. The efficient delivery of MPs is realized by using a functionalized cell membrane of an overexpressed ICAM-1 ligand to wrap nano-particles and by virtue of infiltration and rapid apoptosis of a large number of neutrophils in an inflammatory microenvironment and a process (cell burial effect) of specific phagocytosis of the neutrophils by the MPs. Compared with a traditional targeting scheme, the in-vitro targeting efficiency and the in-vivo targeting efficiency of the FCM-coated siNPs scheme are improved by 360% and 120% respectively. The siRNA is guided to target MPs, and the expression of STING is inhibited, so that the inflammatory reaction caused by mtDNA release is regulated and controlled, and an excellent anti-inflammatory curative effect is shown in an inflammatory model mouse.

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38′ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and / or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CD38 protein.

The invention discloses a blood routine examination and immunochromatography combined detection reagent card, and belongs to the technical field of medical detection, the blood routine examination and immunochromatography combined detection reagent card comprises a reagent card body, the reagent card body comprises a detection counting area, a reagent liquid filling area and a sampling area, the sampling area is used for accommodating a sample and pre-diluting the sample, the reagent liquid filling area is used for treating and diluting the sample, and the detection counting area is used for counting the detection counting area. The detection counting area comprises a red blood cell counting square groove, a white blood cell counting square groove and a blood platelet counting square groove. Five groups of neutrophil, lymphocyte, mononuclear cell, eosinophilic granulocyte and basophilic granulocyte in leukocyte are realized, and promotion of a basic POCT instrument can be promoted by matching with other necessary blood routine parameters and CRP, SAA, glycosylated hemoglobin and other parameters. The operation of a user is convenient, the joint detection test of blood routine examination and immunochromatography items can be fully automatically completed by one reagent card and the immunochromatography card, and extra dilution of a sample is not needed.

The application discloses application of volatile oil of Citrus aurantium in preparation of a medicine for preventing and treating allergic rhinitis. The application proposes that the volatile oil of Citrus aurantium can significantly reduce the levels of mast cell factors IL-1beta and TNF-alpha, and can also significantly reduce the levels of inflammatory factors IL-13 and IL-4 in mice, reduce inflammatory cell infiltration, and reduce eosinophilic granulocyte increase and gland hyperplasia. The application proposes that the volatile oil of Citrus aurantium has great potential as a medicinal and edible raw material for treating allergic rhinitis. The application also proposes that the volatile oil of Citrus aurantium can significantly improve symptoms such as sneezing, runny nose, and nasal itching of mice caused by allergic rhinitis, and the symptoms seriously affect the life of patients.

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds of the following formula (collectively referred to herein as NASMP compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, e.g., multiple myeloma, diffuse large B-cell lymphoma, acute myeloid leukemia, eosinophilic leukemia, glioblastoma, melanoma, ovarian cancer, chemotherapy resistant cancer, radiation resistant cancer, inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus (SLE), lupus nephritis, asthma, chronic obstructive pulmonary disease (COPD), Hidradenitis suppurativa, autoimmune hepatitis, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.